Intelligent medical device developer M3dicine yesterday announced the launch of its Stethee AI-enabled stethoscope system designed to amplify, filter, record and analyze heart and lung sound.
The newly launched, FDA-cleared Stethee Pro features technology to capture and analyze heart and lung sounds and data via Bluetooth, operating around smartphone applications for both Apple iOS and Google Android devices, the Brisbane, Australia-based company said.
“The Stethee system has the potential to transform healthcare. We are on the forefront of a new era in healthcare driven by artificial intelligence and its ability to significantly improve our ability to care for patients. This innovative technology can significantly help drive efficiency and productivity and empower healthcare providers worldwide by providing real time data and clinical interpretation,” Dr. John Sperling of the Mayo Clinic said in a press release.
The Stethee system features the company’s Aida artificial intelligence engine designed to analyze heart and lung sounds to create personal biometric signals. The system is also designed to geo-tag the data, and include environmental data to samples it collects and analyzes.
Sound and data from the device is designed to stream to bluetooth enable audio devices or wired headphones, the company said.
M3dicine said it has inked an exclusive agreement with Korea Telecom for the distribution of its Stethee Pro in a number of developing countries.
“This most iconic and enduring symbol of healthcare is now reinvented, into an intelligent and sophisticated medical device- a powerful diagnostic assistant that becomes more intelligent the more it is used. The complementary Stethee Apps bring the power of machine learning and deep neural networks to health professionals worldwide who can use this data not only to monitor the progress and health of individual patients, but collectively to uncover new patterns and trends to help in the fight against heart and lung disease globally. The potential for Stethee to be used in remote and rural areas is enormous because it’s incredibly easy to use and the results can be shared and analyzed instantly by a medical specialist anywhere in the world. The ability to record, share and compare samples is invaluable to improving patient care, especially for remote and rural clinics where access to screening services or a cardiologist is extremely difficult.” CEO & founder Dr. Nayyar Hussain said in a prepared statement.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.